Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lev Pharmaceuticals has entered into a strategic supply agreement with Plasma Centers of America, to construct and purchase a maximum of three plasma collection centers in the US with exclusive rights to make periodic purchases of US source plasma from each new collection center through December 31, 2010.
Subscribe to our email newsletter
The terms of this agreement are subject to certain provisions and performance targets as outlined in Lev’s filing on Form 8-K with the Securities and Exchange Commission.
Judson Cooper, chairman of Lev, said: “This agreement is aimed at providing Lev with an ancillary source of US plasma supply in anticipation of launch of our lead product candidate, Cinryze, for the treatment of hereditary angioedema, upon FDA approval.”